<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">101124171</journal-id>
<journal-id journal-id-type="pubmed-jr-id">29776</journal-id>
<journal-id journal-id-type="nlm-ta">Nat Rev Drug Discov</journal-id>
<journal-id journal-id-type="iso-abbrev">Nat Rev Drug Discov</journal-id>
<journal-title-group>
<journal-title>Nature reviews. Drug discovery</journal-title>
</journal-title-group>
<issn pub-type="ppub">1474-1776</issn>
<issn pub-type="epub">1474-1784</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">29217836</article-id>
<article-id pub-id-type="pmc">6904225</article-id>
<article-id pub-id-type="doi">10.1038/nrd.2017.221</article-id>
<article-id pub-id-type="manuscript">NIHMS1061581</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Berry-Kravis</surname>
<given-names>Elizabeth M.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lindemann</surname>
<given-names>Lothar</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Jønch</surname>
<given-names>Aia E.</given-names>
</name>
<xref ref-type="aff" rid="A3">3</xref>
<xref ref-type="aff" rid="A4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Apostol</surname>
<given-names>George</given-names>
</name>
<xref ref-type="aff" rid="A5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bear</surname>
<given-names>Mark F.</given-names>
</name>
<xref ref-type="aff" rid="A6">6</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Carpenter</surname>
<given-names>Randall L.</given-names>
</name>
<xref ref-type="aff" rid="A6">6</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Crawley</surname>
<given-names>Jacqueline N.</given-names>
</name>
<xref ref-type="aff" rid="A7">7</xref>
<xref ref-type="aff" rid="A8">8</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Curie</surname>
<given-names>Aurore</given-names>
</name>
<xref ref-type="aff" rid="A9">9</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Des Portes</surname>
<given-names>Vincent</given-names>
</name>
<xref ref-type="aff" rid="A9">9</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hossain</surname>
<given-names>Farah</given-names>
</name>
<xref ref-type="aff" rid="A10">10</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gasparini</surname>
<given-names>Fabrizio</given-names>
</name>
<xref ref-type="aff" rid="A11">11</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gomez-Mancilla</surname>
<given-names>Baltazar</given-names>
</name>
<xref ref-type="aff" rid="A11">11</xref>
<xref ref-type="aff" rid="A12">12</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hessl</surname>
<given-names>David</given-names>
</name>
<xref ref-type="aff" rid="A7">7</xref>
<xref ref-type="aff" rid="A8">8</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Loth</surname>
<given-names>Eva</given-names>
</name>
<xref ref-type="aff" rid="A13">13</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Scharf</surname>
<given-names>Sebastian H.</given-names>
</name>
<xref ref-type="aff" rid="A14">14</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wang</surname>
<given-names>Paul P.</given-names>
</name>
<xref ref-type="aff" rid="A15">15</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Von Raison</surname>
<given-names>Florian</given-names>
</name>
<xref ref-type="aff" rid="A16">16</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hagerman</surname>
<given-names>Randi</given-names>
</name>
<xref ref-type="aff" rid="A7">7</xref>
<xref ref-type="aff" rid="A17">17</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Spooren</surname>
<given-names>Will</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Jacquemont</surname>
<given-names>Sébastien</given-names>
</name>
<xref ref-type="aff" rid="A18">18</xref>
<xref ref-type="aff" rid="A19">19</xref>
</contrib>
</contrib-group>
<aff id="A1"><label>1</label>Departments of Pediatrics, Neurological Sciences and Biochemistry, Rush University Medical Center, 1725 West Harrison Street, Suite 718, Chicago, Illinois 60612, USA.</aff>
<aff id="A2"><label>2</label>Roche Pharmaceuticals Research and Early Development, Discovery Neuroscience, Neuroscience, Ophthalmology, and Rare Diseases, Roche Innovation Center Basel, Grenzacherstrasse 124, 4070 Basel, Switzerland.</aff>
<aff id="A3"><label>3</label>Department of Clinical Genetics, Odense University Hospital, Sdr. Boulevard 29, Odense C, Denmark.</aff>
<aff id="A4"><label>4</label>Human Genetics, Department of Clinical Research, University of Southern Denmark, J.B. Winsløws Vej 19, 5000 Odense C, Denmark.</aff>
<aff id="A5"><label>5</label>Formerly at Neuroscience Development, Novartis Pharma AG, Fabrikstrasse 2, 4056 Basel, Switzerland.</aff>
<aff id="A6"><label>6</label>Picower Institute for Learning and Memory, Massachusetts Institute of Technology, 43 Vassar St, Cambridge, Massachusetts 02139, USA.</aff>
<aff id="A7"><label>7</label>MIND Institute, University of California Davis School of Medicine, 2825 50th Street, Sacramento, California 95817, USA.</aff>
<aff id="A8"><label>8</label>Department of Psychiatry and Behavioral Sciences, University of California Davis School of Medicine, 4625 2nd Avenue, Sacramento, California 95817, USA.</aff>
<aff id="A9"><label>9</label>National Reference Center for Rare Diseases with Intellectual Disability, Hôpital Femme-Mère-Enfant, Hospices Civils de Lyon, Université de Lyon, Institut des Sciences Cognitives, CNRS UMR 5304, Boulevard Pinel 67, 69675 Bron Cedex, France.</aff>
<aff id="A10"><label>10</label>Neuroscience Development, Novartis Pharmaceutical Corporation, 1 Health Plaza, East Hanover, New Jersey 07936, USA.</aff>
<aff id="A11"><label>11</label>Novartis Institutes for Biomedical Research, Neuroscience Research, Postfach, 4002 Basel, Switzerland.</aff>
<aff id="A12"><label>12</label>Department of Neurology &amp; Neurosurgery, McGill University, 845 Sherbrook Street West, Montreal, Quebec H3A 0G4, Canada.</aff>
<aff id="A13"><label>13</label>Sackler Institute for Translational Neurodevelopment, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, De Crespigny Park, Denmark Hill, London SE5 8AF, UK.</aff>
<aff id="A14"><label>14</label>Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Grenzacherstrasse 124, 4070 Basel, Switzerland.</aff>
<aff id="A15"><label>15</label>Simons Foundation, 160 Fifth Avenue, 7th Floor, New York, New York 10010, USA.</aff>
<aff id="A16"><label>16</label>Neuroscience Development, Novartis Pharma AG, Fabrikstrasse 2, 4056 Basel, Switzerland.</aff>
<aff id="A17"><label>17</label>Department of Pediatrics, University of California Davis Medical Center, 2516 Stockton Boulevard, Sacramento, California 95817, USA.</aff>
<aff id="A18"><label>18</label>Service de Génétique Médicale, Centre Hospitalier Universitaire Vaudois, Rue du Bugnon 46, 1011 Lausanne and University of Lausanne, Switzerland.</aff>
<aff id="A19"><label>19</label>Present address: CHU Sainte-Justine Research Centre, University of Montreal, 3175 Chemin de la Côte-Sainte-Catherine, Montreal, Quebec H3T 1C5, Canada.</aff>
<author-notes>
<corresp id="CR1">Correspondence to S.J. <email>sebastien.jacquemont@umontreal.ca</email></corresp>
<fn fn-type="COI-statement" id="FN2">
<p id="P62">Competing interests statement</p>
<p id="P63">The authors declare <underline>competing interests</underline>: see Web version for details.</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>30</day>
<month>11</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="epub">
<day>08</day>
<month>12</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="ppub">
<month>4</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>10</day>
<month>12</month>
<year>2019</year>
</pub-date>
<volume>17</volume>
<issue>4</issue>
<fpage>280</fpage>
<lpage>299</lpage>
<!--elocation-id from pubmed: 10.1038/nrd.2017.221-->
<abstract id="ABS1">
<p id="P2">Neurodevelopmental disorders such as fragile X syndrome (FXS) result in lifelong cognitive and behavioural deficits and represent a major public health burden. FXS is the most frequent monogenic form of intellectual disability and autism, and the underlying pathophysiology linked to its causal gene, <italic>FMR1</italic>, has been the focus of intense research. Key alterations in synaptic function thought to underlie this neurodevelopmental disorder have been characterized and rescued in animal models of FXS using genetic and pharmacological approaches. These robust preclinical findings have led to the implementation of the most comprehensive drug development programme undertaken thus far for a genetically defined neurodevelopmental disorder, including phase IIb trials of metabotropic glutamate receptor 5 (mGluR5) antagonists and a phase III trial of a GABA<sub>B</sub> receptor agonist. However, none of the trials has been able to unambiguously demonstrate efficacy, and they have also highlighted the extent of the knowledge gaps in drug development for FXS and other neurodevelopmental disorders. In this Review, we examine potential issues in the previous studies and future directions for preclinical and clinical trials. FXS is at the forefront of efforts to develop drugs for neurodevelopmental disorders, and lessons learned in the process will also be important for such disorders.</p>
</abstract>
</article-meta>
</front>
</article>
</pmc-articleset>